米勒娃科学 NERV 深 沪
等待开盘 04-01 09:30:00 美东时间
6.025
+0.055
+0.92%
华盛通- 最 高6.255
- 今 开5.85
- 成交量 16.73万股
- 最 低 5.85
- 昨 收 5.97
- 总市值 2.61亿
- 52周最高 12.46
- 市盈率 静 --
- 换手率 0.39%
- 52周最低 1.30
- 委 比 -51.49%
- 总股本 4327.44万
- 历史最高 126.72
- 量 比 0.54
- 振 幅 6.78%
- 历史最低 1.15
- 每 手 1
- 风险率 1.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多快讯 | Minerva Neurosciences 宣布在全球三期确证性试验中，第一名患者已开始接受 Roluperidone 治疗精神分裂症阴性症状的筛查。
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confir...
今天 04:05
Minerva Neurosciences Reveals Data From Its Open-Label Safety Trial Evaluating Roluperidone Co-Administered With Olanzapine At SIRS 2026; Trial Demonstrated No Safety Concerns When Co-Administering Roluperidone And Olanzapine
BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
03-26 04:13
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Minerva Neurosciences presented clinical data at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress demonstrating no significant safety concerns when co-administering roluperidone with olanzapine in patients with negative symptoms of schizophrenia. The trial showed no clinically significant adverse effects, PK changes, or PD changes. Minerva is advancing its program, with a confirmatory Phase 3 trial enrolling and toplin...
03-25 20:05
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
U.S. RESEARCH ROUNDUP-AeroVironment, Bumble, Lumentum Holdings
U.S. RESEARCH ROUNDUP-AeroVironment, Bumble, Lumentum Holdings March 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Thursday, including AeroVironment, Bumble and Lumentum Holdings. HIGHLIGHTS * AeroVironment Inc AVAV.O : Jef
03-12 15:49
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Minerva Neurosciences的执行主席兼首席执行官Remy Luthringer博士将参加于2026年3月17日至18日举办的Stifel 2026虚拟CNS论坛，并于3月18日上午8:30 ET进行公司展示。会议可在Summitcast平台观看，回放将在公司投资者及媒体页面提供90天。Minerva专注于中枢神经系统疾病治疗，正在开展roluperidone的确认性 Phase 3试验以治疗精神分裂症的阴性症状。联系Minerva团队请通过Stifel代表。投资者可联系Frederick Ahlholm或Corey Davis博士。
03-12 11:00
Minerva Neurosciences files $200M mixed shelf registration
Minerva Neurosciences (NERV) filed a $200M shelf registration allowing the company to offer securities from time to time. The offering may include common stock, preferred stock, debt securities, and w...
03-11 21:57
Minerva Neurosciences Files Prospectus To Offer Up To $200M In Common Stock, Preferred Stock, Debt, And Warrants
$200,000,000Common StockPreferred StockDebt SecuritiesWarrantsFrom time to time, we may offer and sell up to $200,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may
03-11 21:23
Minerva Neurosciences Q4 Adj. EPS $(0.64) Misses $(0.30) Estimate
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.30) by 113.33 percent. This is a 14.29 percent decrease over losses of $(0.56) per
03-11 19:25
Minerva Neurosciences GAAP EPS of -$25.51
Minerva Neurosciences press release (NERV): Q4 GAAP EPS of -$25.51. Cash, cash equivalents and restricted cash at December 31, 2025 were approximately $82.4 million, as compared to $21.5 million at De...
03-11 19:12
